GABATHER AB (PUBL) SK-44
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more
Market Cap & Net Worth: GABATHER AB (PUBL) SK-44 (5J2)
GABATHER AB (PUBL) SK-44 (F:5J2) has a market capitalization of $48.49K (€47.24K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #42373 globally and #6599 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GABATHER AB (PUBL) SK-44's stock price €0.00 by its total outstanding shares 236204876 (236.20 Million).
GABATHER AB (PUBL) SK-44 Market Cap History: 2020 to 2026
GABATHER AB (PUBL) SK-44's market capitalization history from 2020 to 2026. Data shows change from $135.29 Million to $48.49K (-76.72% CAGR).
GABATHER AB (PUBL) SK-44 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GABATHER AB (PUBL) SK-44's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 5J2 by Market Capitalization
Companies near GABATHER AB (PUBL) SK-44 in the global market cap rankings as of March 19, 2026.
Key companies related to GABATHER AB (PUBL) SK-44 by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
GABATHER AB (PUBL) SK-44 Historical Marketcap From 2020 to 2026
Between 2020 and today, GABATHER AB (PUBL) SK-44's market cap moved from $135.29 Million to $ 48.49K, with a yearly change of -76.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €48.49K | 0.00% |
| 2025 | €48.49K | -98.96% |
| 2024 | €4.66 Million | -79.57% |
| 2023 | €22.79 Million | -74.49% |
| 2022 | €89.35 Million | -15.87% |
| 2021 | €106.20 Million | -21.51% |
| 2020 | €135.29 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of GABATHER AB (PUBL) SK-44 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.49K USD |
| MoneyControl | $48.49K USD |
| MarketWatch | $48.49K USD |
| marketcap.company | $48.49K USD |
| Reuters | $48.49K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.